{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T04:40:03Z","timestamp":1737434403964,"version":"3.33.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1133701D"],"award-info":[{"award-number":["TCVGH-1133701D"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTCNSTC 112-2314-B-005-011"],"award-info":[{"award-number":["NSTCNSTC 112-2314-B-005-011"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1186\/s12014-025-09527-7","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T04:00:01Z","timestamp":1737432001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink\u00ae proteomics approach"],"prefix":"10.1186","volume":"22","author":[{"given":"Ting-Shuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Ni","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao-Neng","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Pei","family":"Jhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Rung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Lin Jerry","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"7","key":"9527_CR1","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.","journal-title":"Blood Cancer J"},{"key":"9527_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"5","key":"9527_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487\u201394.","journal-title":"J Clin Oncol"},{"issue":"31","key":"9527_CR4","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1200\/JCO.2013.51.4307","volume":"31","author":"TC Ho","year":"2013","unstructured":"Ho TC, Becker MW. Defining patient-specific risk in acute myeloid leukemia. J Clin Oncol. 2013;31(31):3857\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9527_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","volume":"16","author":"NG Daver","year":"2023","unstructured":"Daver NG, Iqbal S, Renard C, Chan RJ, Hasegawa K, Hu H, et al. Treatment outcomes for newly diagnosed, treatment-naive TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. J Hematol Oncol. 2023;16(1):19.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"9527_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/ejh.13301","volume":"103","author":"YC Chiu","year":"2019","unstructured":"Chiu YC, Hsiao TH, Tsai JR, Wang LJ, Ho TC, Hsu SL, et al. Integrating resistance functions to predict response to induction chemotherapy in de novo acute myeloid leukemia. Eur J Haematol. 2019;103(4):417\u201325.","journal-title":"Eur J Haematol"},{"issue":"3","key":"9527_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/hon.3129","volume":"41","author":"PL Cheng","year":"2023","unstructured":"Cheng PL, Hsiao TH, Chen CH, Hung MN, Jhan PP, Lee LW, et al. Chemoresistance in acute myeloid leukemia: an alternative single-cell RNA sequencing approach. Hematol Oncol. 2023;41(3):499\u2013509.","journal-title":"Hematol Oncol"},{"issue":"11","key":"9527_CR8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/s41374-022-00830-7","volume":"102","author":"M Cui","year":"2022","unstructured":"Cui M, Cheng C, Zhang L. High-throughput proteomics: a methodological mini-review. Lab Invest. 2022;102(11):1170\u201381.","journal-title":"Lab Invest"},{"key":"9527_CR9","doi-asserted-by":"publisher","first-page":"104686","DOI":"10.1016\/j.ebiom.2023.104686","volume":"93","author":"MPA Davies","year":"2023","unstructured":"Davies MPA, Sato T, Ashoor H, Hou L, Liloglou T, Yang R, et al. Plasma protein biomarkers for early prediction of lung cancer. EBioMedicine. 2023;93:104686.","journal-title":"EBioMedicine"},{"issue":"6","key":"9527_CR10","first-page":"2030","volume":"54","author":"Y Nakayama","year":"2019","unstructured":"Nakayama Y, Mimura K, Tamaki T, Shiraishi K, Kua LF, Koh V, et al. Phospho\u2013STAT1 expression as a potential biomarker for anti\u2013PD\u20131\/anti\u2013PD\u2013L1 immunotherapy for breast cancer. Int J Oncol. 2019;54(6):2030\u20138.","journal-title":"Int J Oncol"},{"issue":"1","key":"9527_CR11","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1038\/s41467-023-39765-y","volume":"14","author":"MB Alvez","year":"2023","unstructured":"Alvez MB, Edfors F, von Feilitzen K, Zwahlen M, Mardinoglu A, Edqvist PH, et al. Next generation pan-cancer blood proteome profiling using proximity extension assay. Nat Commun. 2023;14(1):4308.","journal-title":"Nat Commun"},{"issue":"3","key":"9527_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","volume":"40","author":"AK Jayavelu","year":"2022","unstructured":"Jayavelu AK, Wolf S, Buettner F, Alexe G, Haupl B, Comoglio F, et al. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell. 2022;40(3):301\u201317. e12.","journal-title":"Cancer Cell"},{"key":"9527_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.nbt.2022.06.005","volume":"71","author":"A Abu Sabaa","year":"2022","unstructured":"Abu Sabaa A, Shen Q, Lennmyr EB, Enblad AP, Gammelgard G, Molin D, et al. Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls. N Biotechnol. 2022;71:21\u20139.","journal-title":"N Biotechnol"},{"key":"9527_CR14","doi-asserted-by":"publisher","first-page":"104235","DOI":"10.1016\/j.ebiom.2022.104235","volume":"83","author":"N Rossi","year":"2022","unstructured":"Rossi N, Lee KA, Bermudez MV, Visconti A, Thomas AM, Bolte LA, et al. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma. EBioMedicine. 2022;83:104235.","journal-title":"EBioMedicine"},{"issue":"6","key":"9527_CR15","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1158\/1535-7163.MCT-09-1077","volume":"9","author":"JZ Tang","year":"2010","unstructured":"Tang JZ, Kong XJ, Kang J, Fielder GC, Steiner M, Perry JK, et al. Artemin-stimulated progression of human non-small cell lung carcinoma is mediated by BCL2. Mol Cancer Ther. 2010;9(6):1697\u2013708.","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"9527_CR16","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/onc.2009.66","volume":"28","author":"J Kang","year":"2009","unstructured":"Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX, et al. Artemin is oncogenic for human mammary carcinoma cells. Oncogene. 2009;28(19):2034\u201345.","journal-title":"Oncogene"},{"issue":"20","key":"9527_CR17","doi-asserted-by":"publisher","first-page":"7404","DOI":"10.1002\/cam4.4228","volume":"10","author":"Z Sun","year":"2021","unstructured":"Sun Z, Wang XH, Wang JY, Wang J, Liu X, Huang RD, et al. Key radioresistance regulation models and marker genes identified by integrated transcriptome analysis in nasopharyngeal carcinoma. Cancer Med-Us. 2021;10(20):7404\u201317.","journal-title":"Cancer Med-Us"},{"issue":"21","key":"9527_CR18","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1523\/JNEUROSCI.0421-18.2018","volume":"38","author":"S Nencini","year":"2018","unstructured":"Nencini S, Ringuet M, Kim DH, Greenhill C, Ivanusic JJ. GDNF, Neurturin, and Artemin activate and sensitize bone afferent neurons and contribute to Inflammatory Bone Pain. J Neurosci. 2018;38(21):4899\u2013911.","journal-title":"J Neurosci"},{"issue":"3","key":"9527_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00441-019-03068-w","volume":"378","author":"J Thai","year":"2019","unstructured":"Thai J, Green AC, Stamp LA, Spencer NJ, Purton LE, Ivanusic J. A population of nonneuronal GFRalpha3-expressing cells in the bone marrow resembles nonmyelinating Schwann cells. Cell Tissue Res. 2019;378(3):441\u201356.","journal-title":"Cell Tissue Res"},{"issue":"10","key":"9527_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.exphem.2005.06.028","volume":"33","author":"CH Shih","year":"2005","unstructured":"Shih CH, van Eeden SF, Goto Y, Hogg JC. CCL23\/myeloid progenitor inhibitory factor-1 inhibits production and release of polymorphonuclear leukocytes and monocytes from the bone marrow. Exp Hematol. 2005;33(10):1101\u20138.","journal-title":"Exp Hematol"},{"issue":"8","key":"9527_CR21","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1158\/1078-0432.CCR-05-2552","volume":"12","author":"D Steinbach","year":"2006","unstructured":"Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A, et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res. 2006;12(8):2434\u201341.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"9527_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/bloodadvances.2019001124","volume":"4","author":"H \u00c7elik","year":"2020","unstructured":"\u00c7elik H, Lindblad KE, Popescu B, Gui GG, Goswami M, Valdez J, et al. Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia. Blood Adv. 2020;4(2):367\u201379.","journal-title":"Blood Adv"},{"issue":"1","key":"9527_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12014-022-09367-9","volume":"19","author":"SJC Gosline","year":"2022","unstructured":"Gosline SJC, Tognon C, Nestor M, Joshi S, Modak R, Damnernsawad A, et al. Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML. Clin Proteom. 2022;19(1):30.","journal-title":"Clin Proteom"},{"issue":"7","key":"9527_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","volume":"39","author":"SK Joshi","year":"2021","unstructured":"Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. 2021;39(7):999\u2013e10148.","journal-title":"Cancer Cell"},{"issue":"1","key":"9527_CR25","doi-asserted-by":"publisher","first-page":"101359","DOI":"10.1016\/j.xcrm.2023.101359","volume":"5","author":"JC Pino","year":"2024","unstructured":"Pino JC, Posso C, Joshi SK, Nestor M, Moon J, Hansen JR, et al. Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia. Cell Rep Med. 2024;5(1):101359.","journal-title":"Cell Rep Med"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-025-09527-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-025-09527-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-025-09527-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T04:00:05Z","timestamp":1737432005000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalproteomicsjournal.biomedcentral.com\/articles\/10.1186\/s12014-025-09527-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9527"],"URL":"https:\/\/doi.org\/10.1186\/s12014-025-09527-7","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"value":"1542-6416","type":"print"},{"value":"1559-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Taichung Veterans General Hospital following the latest version of the Declaration of Helsinki (CF17319B). All the participants provided informed consent before participating in the study. The patient details were anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We confirm that the material is original research, has not been published elsewhere in part or in entirety and is not under consideration by another journal. All authors have approved the manuscript and agree with its submission to Clinical Proteomics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Chieh-Lin Jerry Teng received honorarium and consulting fees from Novartis, Roche, Pfizer, Takeda, Johnson and Johnson, Amgen, BMS Celgene, Kirin, and MSD. The other authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}